用Atogepant预防性治疗偏头痛的早期改善:来自3个随机第三期试验的结果
Richard B Lipton1, Pranav Gandhi2, Cristina Tassorelli3,4
1Department of Neurology and Headache Center, Albert Einstein College of Medicine, Bronx, NY.
Neurology
|December 23, 2024
概括
阿托杰邦 (Atogepant) 是一种口服的与卡尔西托尼基因相关的受体对手,在4周内显著改善了预防偶发性和慢性偏头痛的疗效和功能结果. 这种口服CGRP抗剂为偏头痛患者提供了快速缓解.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 三个第3期试验 (ADVANCE,ELEVATE,PROGRESS) 评估了阿托基潘特用于偶发性偏头痛 (EM) 和慢性偏头痛 (CM).
- 这一分析主要集中在最初的4周治疗中,每天服用一次60毫克的阿托杰潘特 (atogepant).
研究的目的:
- 评估阿托基潘特在偏头痛预防中的早期疗效和功能改善.
- 评估EM和CM患者在治疗的前4周内的结果.
主要方法:
- 利用了三项随机,双盲,安慰剂控制的第三期试验的数据.
- 测量有效性终点包括偏头痛的一天在第一天,每周和每月偏头痛日的变化 (WMD/MMD).
- 使用"偏头痛日记中的活动障碍" (AIM-D) 和EQ-5D-5L.评估功能结果.
主要成果:
- 与安慰剂相比,Atogepant在所有三项试验中显著降低了第一天患上偏头痛的参与者比例.
- 在最初的4周内,Atogepant治疗导致了大规模杀伤性武器和大规模杀伤性武器的更大减少.
- 与安慰剂相比,使用阿托盖班特观察到AIM-D和EQ-5D-5L得分的显著改善.
结论:
- 在治疗的前4周内,阿托杰潘特60毫克QD在疗效和功能性措施上表现出优于安慰剂的优势.
- 这些发现支持了atogepant在预防性治疗EM和CM中的快速起作用.
相关概念视频
01:11Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
01:24Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
01:27Open Angle Glaucoma: Treatment
391
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
391
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
405
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
405
01:28Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K